Literature DB >> 33515302

Comparison of postoperative analgesic effects in response to either dexamethasone or dexmedetomidine as local anesthetic adjuvants: a systematic review and meta-analysis of randomized controlled trials.

Zhen-Guo Song1, Shen-Yue Pang2, Gui-Yue Wang2, Zhao Zhang2.   

Abstract

This review compares the effects of peripheral dexamethasone and dexmedetomidine on postoperative analgesia. We included six randomized controlled trials (354 patients) through a systematic literature search. We found that analgesia duration was comparable between dexamethasone and dexmedetomidine (58.59 min, 95% CI (confidence interval), -  66.13, 183.31 min) with extreme heterogeneity. Secondary outcome was also compared and no significant difference was observed in sensory block onset and duration and motor block duration and also for postoperative nausea and vomiting. It is noteworthy that dexamethasone reduced analgesic consumption (fentanyl) by 29.12 mcg compared with dexmedetomidine. We performed subgroup analyses and found no significant difference between the following: (1) lidocaine vs ropivacaine (P = 0.28), (2) nerve block vs nerve block + general anesthesia (P = 0.47), and (3) upper limb surgery vs thoracoscopic pneumonectomy (P = 0.27). We applied trial sequential analysis to assess the risks of type I and II errors and concluded that the meta-analysis was insufficiently powered to answer the clinical question, and further analysis is needed to establish which adjuvant is better. In conclusion, we believe that existing research indicates that dexamethasone and dexmedetomidine have equivalent analgesic effects in peripheral nerve blocks.

Entities:  

Keywords:  Adjuvants; Analgesia; Dexamethasone; Dexmedetomidine; Nerve block

Year:  2021        PMID: 33515302      PMCID: PMC7969577          DOI: 10.1007/s00540-021-02895-y

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  35 in total

1.  Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.

Authors:  Jørn Wetterslev; Kristian Thorlund; Jesper Brok; Christian Gluud
Journal:  J Clin Epidemiol       Date:  2007-08-23       Impact factor: 6.437

2.  Co-administration of dexamethasone with peripheral nerve block: intravenous vs perineural application: systematic review, meta-analysis, meta-regression and trial-sequential analysis.

Authors:  M Heesen; M Klimek; G Imberger; S E Hoeks; R Rossaint; S Straube
Journal:  Br J Anaesth       Date:  2017-11-22       Impact factor: 9.166

3.  Randomized comparison between perineural dexamethasone and dexmedetomidine for ultrasound-guided infraclavicular block.

Authors:  Julián Aliste; Sebastián Layera; Daniela Bravo; Diego Fernández; Álvaro Jara; Armando García; Roderick J Finlayson; De Q Tran
Journal:  Reg Anesth Pain Med       Date:  2019-07-11       Impact factor: 6.288

4.  A multicenter, randomized comparison between 2, 5, and 8 mg of perineural dexamethasone for ultrasound-guided infraclavicular block.

Authors:  Daniela Bravo; Julian Aliste; Sebastián Layera; Diego Fernández; Prangmalee Leurcharusmee; Artid Samerchua; Amornrat Tangjitbampenbun; Arraya Watanitanon; Vanlapa Arnuntasupakul; Choosak Tunprasit; Aida Gordon; Roderick J Finlayson; De Q Tran
Journal:  Reg Anesth Pain Med       Date:  2019-01       Impact factor: 6.288

Review 5.  Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis.

Authors:  F W Abdallah; R Brull
Journal:  Br J Anaesth       Date:  2013-04-15       Impact factor: 9.166

6.  Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.

Authors:  Chad M Brummett; Mary A Norat; John M Palmisano; Ralph Lydic
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

7.  Dexamethasone Is Superior to Dexmedetomidine as a Perineural Adjunct for Supraclavicular Brachial Plexus Block: Systematic Review and Indirect Meta-analysis.

Authors:  Eric Albrecht; Leon Vorobeichik; Alain Jacot-Guillarmod; Nicolas Fournier; Faraj W Abdallah
Journal:  Anesth Analg       Date:  2019-03       Impact factor: 5.108

8.  Comparison of dexmedetomidine and dexamethasone as adjuvant for ropivacaine in ultrasound-guided erector spinae plane block for video-assisted thoracoscopic lobectomy surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Zhixin Gao; Yimin Xiao; Qing Wang; Yuanhai Li
Journal:  Ann Transl Med       Date:  2019-11

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

10.  Dexamethasone or Dexmedetomidine as Local Anesthetic Adjuvants for Ultrasound-guided Axillary Brachial Plexus Blocks with Nerve Stimulation.

Authors:  Myeong Jong Lee; Dae Jeong Koo; Yu Sun Choi; Kyu Chang Lee; Hye Young Kim
Journal:  Korean J Pain       Date:  2016-01-04
View more
  3 in total

1.  Ropivacaine with Dexmedetomidine or Dexamethasone in a Thoracic Paravertebral Nerve Block Combined with an Erector Spinae Plane Block for Thoracoscopic Lobectomy Analgesia: A Randomized Controlled Trial.

Authors:  Jing Yang; Min Zhao; Xiao-Rui Zhang; Xiao-Rui Wang; Zhi-Hao Wang; Xiao-Yue Feng; Ya-Juan Lei; Jian-Wen Zhang
Journal:  Drug Des Devel Ther       Date:  2022-05-26       Impact factor: 4.319

2.  Effect of Dexmedetomidine Combined with Ropivacaine on Cognitive Dysfunction and Inflammatory Response in Patients Undergoing Craniocerebral Surgery.

Authors:  Yang Liu; Hongwei Zhang; Wenhua Zhang
Journal:  Biomed Res Int       Date:  2021-11-30       Impact factor: 3.411

3.  Patient-Controlled Intravenous Analgesia with or without Ultrasound-Guided Bilateral Intercostal Nerve Blocks in Children Undergoing the Nuss Procedure: A Randomized, Double-Blinded, Controlled Trial.

Authors:  Bingjie Ma; Yuan Sun; Can Hao; Xiaoming Liu; Sai'e Shen
Journal:  Pain Res Manag       Date:  2022-07-22       Impact factor: 2.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.